383 related articles for article (PubMed ID: 33169506)
21. Selpercatinib for adult patients with locally advanced or metastatic RET-altered solid tumors.
Le D; Konda B
Expert Rev Anticancer Ther; 2023; 23(11):1117-1122. PubMed ID: 37795873
[TBL] [Abstract][Full Text] [Related]
22. Management of Advanced Medullary Thyroid Carcinoma: Current Systemic Therapy Options.
Jara MA
Crit Rev Oncog; 2024; 29(3):83-90. PubMed ID: 38683155
[TBL] [Abstract][Full Text] [Related]
23. Medullary Thyroid Cancer: Updates and Challenges.
Gild ML; Clifton-Bligh RJ; Wirth LJ; Robinson BG
Endocr Rev; 2023 Sep; 44(5):934-946. PubMed ID: 37204852
[TBL] [Abstract][Full Text] [Related]
24. Selpercatinib for lung and thyroid cancers with RET gene mutations or fusions.
Zheng H; Chen ZS; Li J
Drugs Today (Barc); 2021 Oct; 57(10):621-629. PubMed ID: 34713870
[TBL] [Abstract][Full Text] [Related]
25. Selective RET kinase inhibition for patients with RET-altered cancers.
Subbiah V; Velcheti V; Tuch BB; Ebata K; Busaidy NL; Cabanillas ME; Wirth LJ; Stock S; Smith S; Lauriault V; Corsi-Travali S; Henry D; Burkard M; Hamor R; Bouhana K; Winski S; Wallace RD; Hartley D; Rhodes S; Reddy M; Brandhuber BJ; Andrews S; Rothenberg SM; Drilon A
Ann Oncol; 2018 Aug; 29(8):1869-1876. PubMed ID: 29912274
[TBL] [Abstract][Full Text] [Related]
26. Selpercatinib Treatment of RET-Mutated Thyroid Cancers Is Associated With Gastrointestinal Adverse Effects.
Tsang V; Gill A; Gild M; Lurie B; Blumer L; Siddall R; Clifton-Bligh R; Robinson B
J Clin Endocrinol Metab; 2022 Aug; 107(9):e3824-e3829. PubMed ID: 35647935
[TBL] [Abstract][Full Text] [Related]
27. Selpercatinib.
Am J Health Syst Pharm; 2020 Oct; 77(22):1818-1821. PubMed ID: 32930710
[No Abstract] [Full Text] [Related]
28. Precision Targeted Therapy with BLU-667 for
Subbiah V; Gainor JF; Rahal R; Brubaker JD; Kim JL; Maynard M; Hu W; Cao Q; Sheets MP; Wilson D; Wilson KJ; DiPietro L; Fleming P; Palmer M; Hu MI; Wirth L; Brose MS; Ou SI; Taylor M; Garralda E; Miller S; Wolf B; Lengauer C; Guzi T; Evans EK
Cancer Discov; 2018 Jul; 8(7):836-849. PubMed ID: 29657135
[TBL] [Abstract][Full Text] [Related]
29. Chylous effusions in advanced medullary thyroid cancer patients treated with selpercatinib.
Prete A; Gambale C; Cappagli V; Bottici V; Rossi P; Caciagli M; Papini P; Taddei D; Ortori S; Gabbrielli L; Celi A; Materazzi G; Elisei R; Matrone A
Eur J Endocrinol; 2022 Dec; 187(6):905-915. PubMed ID: 36314655
[TBL] [Abstract][Full Text] [Related]
30. FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with
Bradford D; Larkins E; Mushti SL; Rodriguez L; Skinner AM; Helms WS; Price LSL; Zirkelbach JF; Li Y; Liu J; Charlab R; Turcu FR; Liang D; Ghosh S; Roscoe D; Philip R; Zack-Taylor A; Tang S; Kluetz PG; Beaver JA; Pazdur R; Theoret MR; Singh H
Clin Cancer Res; 2021 Apr; 27(8):2130-2135. PubMed ID: 33239432
[TBL] [Abstract][Full Text] [Related]
31. Systemic treatment and management approaches for medullary thyroid cancer.
Ernani V; Kumar M; Chen AY; Owonikoko TK
Cancer Treat Rev; 2016 Nov; 50():89-98. PubMed ID: 27664392
[TBL] [Abstract][Full Text] [Related]
32. Spontaneous and Treatment-Related Changes of Serum Calcitonin in Medullary Thyroid Cancer: Long-Term Experience in a Patient With Multiple Endocrine Neoplasia Type 2B.
Réti Z; Tabák ÁG; Garami M; Kalina I; Kiss G; Sápi Z; Tóth M; Tőke J
JCO Precis Oncol; 2024 May; 8():e2300675. PubMed ID: 38709988
[TBL] [Abstract][Full Text] [Related]
33. Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma.
Schrenk KG; Weschenfelder W; Spiegel C; Agaimy A; Stöhr R; Hartmann A; Gaßler N; Drescher R; Freesmeyer M; Malouhi A; Bürckenmeyer F; Aschenbach R; Teichgräber U; Kögler C; Vogt M; Hofmann GO; Hochhaus A
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5493-5496. PubMed ID: 36469155
[TBL] [Abstract][Full Text] [Related]
34. Transcriptional targeting of oncogene addiction in medullary thyroid cancer.
Valenciaga A; Saji M; Yu L; Zhang X; Bumrah C; Yilmaz AS; Knippler CM; Miles W; Giordano TJ; Cote GJ; Ringel MD
JCI Insight; 2018 Aug; 3(16):. PubMed ID: 30135308
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma.
Heilmann AM; Subbiah V; Wang K; Sun JX; Elvin JA; Chmielecki J; Sherman SI; Murthy R; Busaidy NL; Subbiah I; Yelensky R; Nangia C; Vergilio JA; Khan SA; Erlich RL; Lipson D; Ross JS; Miller VA; Shah MH; Ali SM; Stephens PJ
Oncology; 2016; 90(6):339-46. PubMed ID: 27207748
[TBL] [Abstract][Full Text] [Related]
36. FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With
Kim J; Bradford D; Larkins E; Pai-Scherf LH; Chatterjee S; Mishra-Kalyani PS; Wearne E; Helms WS; Ayyoub A; Bi Y; Sun J; Charlab R; Liu J; Zhao H; Liang D; Ghosh S; Philip R; Pazdur R; Theoret MR; Beaver JA; Singh H
Clin Cancer Res; 2021 Oct; 27(20):5452-5456. PubMed ID: 34045295
[TBL] [Abstract][Full Text] [Related]
37. Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Kurzrock R; Atkins J; Wheler J; Fu S; Naing A; Busaidy N; Hong D; Sherman S
Ann Oncol; 2013 Sep; 24(9):2256-61. PubMed ID: 23676418
[TBL] [Abstract][Full Text] [Related]
38. T Cells Engineered to Express Immunoreceptors Targeting the Frequently Expressed Medullary Thyroid Cancer Antigens Calcitonin, CEA, and RET M918T.
Erickson TA; Shih YP; Fass J; Jang M; Tran E
Thyroid; 2022 Jul; 32(7):789-798. PubMed ID: 35587601
[No Abstract] [Full Text] [Related]
39. Successful Treatment with Selpercatinib for Ectopic Cushing's Syndrome Due to Medullary Thyroid Cancer.
Ragnarsson O; Piasecka M; Hallqvist A
Curr Oncol; 2022 May; 29(5):3494-3498. PubMed ID: 35621672
[TBL] [Abstract][Full Text] [Related]
40. Management of Medullary Thyroid Cancer.
Viola D; Elisei R
Endocrinol Metab Clin North Am; 2019 Mar; 48(1):285-301. PubMed ID: 30717909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]